Abstract
The potential of the prostate cancer antigen 3 (PCA3) urine assay to aid prostate cancer diagnosis and minimize unnecessary biopsies has been extensively studied. Results from three recent studies that compared the performance of PCA3 with PSA underscore the advancement and future challenges for this new diagnostic biomarker.
Original language | English |
---|---|
Pages (from-to) | 123-124 |
Number of pages | 2 |
Journal | Nature Reviews Urology |
Volume | 8 |
Issue number | 3 |
DOIs | |
State | Published - Apr 2011 |
Externally published | Yes |